Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Dondossola, Eleonora ^a   Corti, Angelo ^b   Sidman, Richard L ^c,d   Arap, Wadih ^e,f   Pasqualini, Renata ^e,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bone marrow derived cells; CD13; Mouse models; Tumor

Indexed keywords

GELATINASE B; MICROSOMAL AMINOPEPTIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; BREAST ADENOCARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CD11B+ CD13+ MYELOID CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SUBPOPULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; IMMUNOREACTIVITY; KERATINOCYTE; LEWIS CARCINOMA; MACROPHAGE; MAST CELL; MELANOMA; NONHUMAN; PERICYTE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

EID: 84899128535     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27716     Document Type: Article

References (10)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49; PMID:18463380; http://dx.doi. org/10.1056/NEJMra0706596.
2. De Palma M, Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006; 1766:159-66; PMID:16857321.
3. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 2010; 176:1564-76; PMID:20167863; http://dx.doi.org/10.2353/ajpath.2010.090786.
4. Guzman-Rojas L, Rangel R, Salameh A, Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ, Kolonin MG, Staquicini FI, et al. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci U S A 2012; 109:1637-42; PMID:22307623; http://dx.doi. org/10.1073/pnas.1120790109.
5. Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 2008; 14:361-71; PMID:18603472; http://dx.doi. org/10.1016/j.molmed.2008.06.003.
6. Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, Giordano RJ, Van Pelt CS, Tinkey PT, Behringer RR, Sidman RL, et al. Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A 2007; 104:4588-93; PMID:17360568; http://dx.doi. org/10.1073/pnas.0611653104.
7. Dondossola E, Rangel R, Guzman-Rojas L, Barbu EM, Hosoya H, St John LS, Molldrem JJ, Corti A, Sidman RL, Arap W, et al. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 2013; 110:20717-22; PMID:24297924; http://dx.doi.org/10.1073/pnas.1321139110.
8. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev 2012; 32:1078-91; PMID:21287572; http://dx.doi.org/10.1002/med.20238.
9. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-80; PMID:9430587; http://dx.doi.org/10.1126/science.279.5349.377.
10. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60:722-7; PMID:10676659.